Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 113Neoplasms 8HER2-positive Breast Cancer 8Neoplasm Metastasis 6Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Inflammatory Breast Neoplasms 4Hematologic Neoplasms 3Brain Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Locally Advanced Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × pertuzumab × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡